Sexual Dysfunction

Steven A. Kaplan, MD, introduces #LetsTalkMensHealth, a novel new section in Urology Times focused on men’s health.

Other products featured include a testosterone gel, exercise program to strengthen male pelvic muscles, and a book about prostate cancer diagnosis and management.

The Androgen Study Group has called upon the Journal Oversight Committee to investigate what it deemed violations of “accepted standards of medical journal ethics and editorial integrity” by JAMA.

Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.

To gain an endocrinologist’s perspective on current issues in testosterone therapy and hypogonadism, Urology Times interviewed Rebecca Z. Sokol MD, MPH, professor of obstetrics and gynecology and medicine at the Keck School of Medicine of the University of Southern California, Los Angeles.

All treatments entail some risk, including T therapy. At this point, there are no compelling data to support the notion that T therapy is associated with CV risks, and there is suggestive evidence it may even be helpful.

The FDA has rejected Public Citizen’s petition to have a black box warning placed on the labels of testosterone-containing drugs available in the United States.

Prospective, long-term follow-up in a large cohort of hypogonadal men treated with testosterone replacement therapy (TRT) provides no evidence that TRT increases the risk for prostate cancer.

Symptomatic hypogonadal men treated with clomiphene citrate (Clomid) or testosterone gels report similar satisfaction levels as age-matched men treated with testosterone injections, despite having significantly lower serum total testosterone levels, according to the findings of a recent retrospective study from Baylor College of Medicine, Houston.

Testosterone replacement therapy has been much debated in recent months, in light of two studies linking the treatment to increased risk of all-cause mortality, myocardial infarction, and stroke, prompting an FDA investigation into TRT’s safety and widespread criticism from members of the urologic community. In this article, Ajay Nehra, MD, discusses those studies, evolving attitudes toward “low T,” and the importance of individualizing treatment.

Men are being too easily enticed lately into ill-advised use of testosterone supplementation. Even men with only minimal, vague complaints are promised a hormonal fountain of youth and ageless virility. Many potential candidates seem to be under the misconception that “T” replacement will boost or energize their natural testicular production. In fact, exogenous testosterone suppresses testicular function.

Landon Trost, MD, presents the take home messages on sexual function/dysfunction from the AUA annual meeting in Orlando, FL, including studies of clostridium collagenase histolyticum (CCH [XIAFLEX]).

Richard K. Lee, MD, MBA, presents the take home messages on BPH/LUTS from the AUA annual meeting in Orlando, FL.

K.C. Balaji, MD, presents the take home messages on basic science research from the AUA annual meeting in Orlando, FL.

Tobias S. Köhler, MD, MPH, presents the take home messages on infertility/andrology from the AUA annual meeting in Orlando, FL.

I consider urology to be a very unique field, one that I am lucky to be part of. Recently, though, I have begun to wonder whether the medical community (not necessarily the urology community) has been too quick to embrace the widespread use of testosterone replacement therapy.

New urology products and services from Symtelligence Medical Informatics, LABORIE, Metamark Genetics, the MediSafe Project, and Olympus

A recent large study has found no increased risk of heart attack in men undergoing testosterone replacement therapy.

Testosterone replacement therapy is in the news again, for reasons both good and bad.

New products and services from TERUMO Medical Corp., TOLMAR Pharmaceuticals, Spry Publishing, and Beckman Coulter Diagnostics.

The FDA has approved a new testosterone gel formulation, marking the agency’s second approval of a testosterone replacement therapy in the course of a week.

The FDA has approved a nasal gel for men with hypogonadism and has granted clearance to a treatment for urinary incontinence in men. Separately, two drug makers are approaching the agency about regulatory approval for an over-the-counter version of a phosphodiesterase-type-5 inhibitor.

Drugs in the pipeline from Astellas Pharma, Medivation, TesoRx, Strategic Science and Technologies, Cubist Pharmaceuticals, and SCA.

The recently concluded AUA annual meeting in Orlando may not go down as one of the most memorable annual meetings in recent years. Nevertheless, it was noteworthy for some interesting news and lively debate on hot-button topics: the safety of certain urologic products, namely, testosterone and transvaginal mesh; new tests for prostate cancer; infection prevention and treatment; and use of an advanced prostate cancer agent in the pre-chemotherapy setting.

Testosterone replacement therapy may be considered for treatment of hypogonadism in carefully selected men who have undergone radical prostatectomy for low- to intermediate-risk prostate cancer, according to researchers from New York University Medical Center, New York.